Chris Yates

Company: Rgenta Therapeutics

Job title: Executive Director & Head of Medicinal Chemistry

Seminars:

Developing RNA-Modulating Oral Small Molecules Targeting PMS1 to Treat Incurable Neurological Disorders 9:00 am

Leveraging our proprietary, integrative RNA-targeting small molecule discovery platform to pioneer the development of first-in-class oral therapies Pursuing oncology and neurological disease targets, exemplified by the oncogenic transcription factor target c-MYB and the PMS1 gene PMS1 is a key component of the DNA mismatch repair pathway, implicated in the pathological somatic trinucleotide repeat expansion observed…Read more

day: Day Two